» Articles » PMID: 24632279

Impact of Coronary Lesion Complexity on Drug-eluting Stent Outcomes in Patients with and Without Diabetes Mellitus: Analysis from 18 Pooled Randomized Trials

Overview
Date 2014 Mar 18
PMID 24632279
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aim of this study was to investigate whether baseline lesion complexity affects drug-eluting stent (DES) outcomes according to diabetic status.

Background: Previous studies have reported conflicting results regarding DES safety and efficacy in patients with and without diabetes mellitus (DM).

Methods: Patient-level data from 18 prospective randomized trials were pooled. DES treatment outcomes in patients with versus without DM were analyzed in 2 propensity score-matched groups further stratified according to lesion complexity (American College of Cardiology and American Heart Association class A/B1 vs. B2/C). Remaining baseline differences were adjusted for by multivariate analysis.

Results: DM was present in 3,467 of 18,441 patients (18.8%). DM was a predictor of 1-year repeat revascularization (target lesion revascularization: hazard ratio: 1.34; 95% confidence interval: 1.05 to 1.70; target vessel revascularization: hazard ratio: 1.40; 95% confidence interval: 1.15 to 1.72) and cardiac death or myocardial infarction (hazard ratio: 1.40; 95% confidence interval: 1.09 to 1.81). Rates of target lesion and target vessel revascularization were significantly higher in patients with versus those without DM with type B2/C lesions (8.0% vs. 4.5% and 10.6% vs. 5.9%, respectively, p < 0.0001 for both), but not in patients with only type A/B1 lesions (4.6% vs. 4.8%, p = 0.87, and 7.4% vs. 6.8%, p = 0.47, respectively), with a significant interaction between DM and lesion type observed for both endpoints (p = 0.01 and p = 0.02, respectively). No interaction was observed for death or myocardial infarction (p = 0.28).

Conclusions: In the DES era, patients with DM remain at increased risk for cardiac death or myocardial infarction. However, DM is a risk factor for repeat revascularization only in those patients with complex lesions; patients with DM and noncomplex lesions have similar rates of 1-year freedom from repeat revascularization as do patients without DM.

Citing Articles

Elderly patients treated with Onyx versus Orsiro drug-eluting coronary stents in a randomized clinical trial with long-term follow-up.

van Vliet D, Ploumen E, Pinxterhuis T, Doggen C, Aminian A, Schotborgh C Clin Res Cardiol. 2025; .

PMID: 40035811 DOI: 10.1007/s00392-025-02622-7.


Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus.

Thomas A, Kereiakes D, Baumbach A, Windecker S, Pietras C, Dressler O J Soc Cardiovasc Angiogr Interv. 2024; 1(2):100033.

PMID: 39132558 PMC: 11307809. DOI: 10.1016/j.jscai.2022.100033.


Patients With Diabetes at High Bleeding Risk With 1-Month Dual Antiplatelet Therapy: Onyx ONE Clear Results.

Kedhi E, Windecker S, Latib A, Kirtane A, Kandzari D, Mehran R J Soc Cardiovasc Angiogr Interv. 2024; 1(5):100441.

PMID: 39131461 PMC: 11307822. DOI: 10.1016/j.jscai.2022.100441.


Intravascular Imaging and Angiography Guidance in Complex Percutaneous Coronary Intervention Among Patients With Diabetes: A Secondary Analysis of a Randomized Clinical Trial.

Choi K, Park T, Song Y, Lee J, Lee J, Lee S JAMA Netw Open. 2024; 7(6):e2417613.

PMID: 38913377 PMC: 11197449. DOI: 10.1001/jamanetworkopen.2024.17613.


Cardiovascular and Bleeding Events of Ticagrelor Monotherapy after Short-term Dual Antiplatelet Therapy (DAPT) in Diabetics and Non-Diabetics Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.

Sadeghi M, Kermani-Alghoraishi M, Khosravi A, Amerizadeh A, Sadeghi M ARYA Atheroscler. 2024; 19(3):43-53.

PMID: 38881589 PMC: 11066786. DOI: 10.48305/arya.2022.26680.2821.